Boris Schlenker

Boris Schlenker

Auto-generated profile, based on publicly available information

Boris Schlenker

Department of Urology, Klinikum der Universität München, Munich, Germany

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
BSBoris Schlenker
Boris Schlenker
BSBernhard Scher
Bernhard Scher
RTReinhold Tiling
Reinhold Tiling
SSSabine Siegert
Sabine Siegert
EHEdwin Hungerhuber
Edwin Hungerhuber
MSMichael Seitz
Michael Seitz

1 June 2006 in European Urology
Verified
Journal Article
Closed access
BSBoris Schlenker
Boris Schlenker
CGChristian Gratzke
Christian Gratzke
OROliver Reich
Oliver Reich
ISIsabel Schorsch
Isabel Schorsch
MSMichael Seitz
Michael Seitz
CSChristian G. Stief
Christian G. Stief

26 August 2010 in BJU International
Verified
Journal Article
Open access
PDF file
BSBoris Schlenker
Boris Schlenker
DTDerya Tilki
Derya Tilki
MSMichael Seitz
Michael Seitz
MBMarkus J. Bader
Markus J. Bader
OROliver Reich
Oliver Reich
CGChristian Gratzke
Christian Gratzke
Study Type – Therapy (case series) Level of Evidence 4 OBJECTIVE: To retrospectively analyse the long‐term follow‐up of 54 patients treated with organ‐preserving laser therapy for penile carcinoma, as such therapy provides excellent cosmetic and functional results, but recurrence rates are high, which might impair the oncological outcome and worsen tumour‐related survival. PATIENTS AND METHODS: Between 1979 and 2008, 54 patients with penile carcinoma were treated with the neodymium‐doped yttrium‐aluminium‐garnet (Nd:YAG) laser at our institution; 11 were classified as having carcinoma in situ (Tis), 39 as T1 and four as T2. RESULTS: There was local recurrence in 16 patients (42%); the mean (range) time to local recurrence was 53 (9–132) months. In half the patients the time to local recurrence was >53 months, with the latest recurrence at 132 months after initial therapy of primary tumour. There was no statistically significant difference in recurrence rates with Tis or invasive penile carcinoma. In lymph‐node‐negative patients at initial presentation, there were no newly developed positive lymph nodes during the follow‐up. CONCLUSIONS: Organ‐preserving laser therapy showed a relatively high recurrence rate in patients with a long‐term follow up, but the oncological outcome and survival were not compromised by local recurrence. Therefore, laser therapy appears to be appropriate for treating premalignant lesions and early stages of penile carcinoma. Patients should be informed about the potential for late recurrence.

11 September 2022 in Cancers
Verified
Journal Article
Open access
PDF file
SRSeverin Rodler
Severin Rodler
LELennert Eismann
Lennert Eismann
BSBoris Schlenker
Boris Schlenker
JCJozefina Casuscelli
Jozefina Casuscelli
IBIsabel Brinkmann
Isabel Brinkmann
SLStephan Ledderose
Stephan Ledderose
Variant histologies of bladder cancer (BC) often present with advanced tumor stage and the status of perioperative therapy is unclear. Thereby, squamous cell carcinoma (SCC), adenocarcinoma (ADENO), and sarcomatoid urothelial carcinoma (SARCO) are the most frequent variants. Nectin-4 has emerged as a highly interesting target in BC and might guide therapeutic application of antibody–drug conjugates (ADC). We therefore aimed to investigate expression patterns and prognostic value of Nectin-4 in variant histologies of BC. A single-center retrospective analysis was conducted of patients who underwent radical cystectomy (RC) for BC and revealed variant histologies of BC in the final specimens. Immunohistochemical staining for Nectin-4 was performed on tissue microarrays with 59 SCC, 22 ADENO, and 24 SARCO, and Nectin-4 expression was scored using the histochemical scoring system (H-score). Overall survival (OS) and progression-free survival (PFS) was calculated by Kaplan–Meier method. Median expression of Nectin-4 was 150 (range 0–250) in SCC, 140.5 (range 30–275) in ADENO, and 10 (0–185) in SARCO, with significantly lower levels for SARCO compared to SCC or ADENO (p < 0.001). For SCC, ADENO or SARCO no differences regarding OS or PFS were observed based on Nectin-4 expression levels (p > 0.05). Multivariate analysis revealed nodal stage as an independent prognostic factor for OS and PFS and metastases for PFS but not Nectin-4 expression. In conclusion, Nectin-4 was not prognostic in histological subtypes of BC in our study cohort. However, the high expression of Nectin-4 in SCC and ADENO might guide future treatment with novel Nectin-4-directed ADCs and provide this high-risk patient collective with a new promising therapeutic option. Testing Nectin-4 expression as a biomarker should be considered in trials with SARCO, where low Nectin-4 expression has been observed.

1 January 2019 in European Urology Focus
Verified
Journal Article
Closed access
BSBoris Schlenker
Boris Schlenker
PSPeter Schneede
Peter Schneede

1 November 2011 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
BSBoris Schlenker
Boris Schlenker
CGChristian Gratzke
Christian Gratzke
MSMichael Seitz
Michael Seitz
MBMarkus J. Bader
Markus J. Bader
OROliver Reich
Oliver Reich
DTDerya Tilki
Derya Tilki